Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion

NCT01428388 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Retinal Vein Occlusion
Macular Edema

Interventions

DRUG: Intravitreal injection of bevacizumab
DRUG: Intravitreal injection of ranibizumab (0.5 mg per dose)

Sponsor

Barnes Retina Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]